Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,039 shares of the medical equipment provider’s stock after selling 600 shares during the period. Gilman Hill Asset Management LLC’s holdings in Zimmer Biomet were worth $2,962,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ZBH. Geode Capital Management LLC boosted its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after acquiring an additional 125,852 shares in the last quarter. Van ECK Associates Corp increased its stake in Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after purchasing an additional 411,163 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Zimmer Biomet by 0.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider’s stock worth $277,357,000 after purchasing an additional 9,990 shares in the last quarter. Hotchkis & Wiley Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after buying an additional 577,320 shares in the last quarter. Finally, Magnetar Financial LLC raised its stake in Zimmer Biomet by 58.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock worth $142,203,000 after acquiring an additional 484,816 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on ZBH shares. Royal Bank of Canada upped their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Barclays cut their price target on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday, December 12th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Finally, Wells Fargo & Company increased their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $123.33.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $109.65 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a one year low of $100.67 and a one year high of $133.90. The firm has a market capitalization of $21.83 billion, a P/E ratio of 20.85, a PEG ratio of 1.79 and a beta of 1.02. The company’s fifty day moving average is $107.84 and its two-hundred day moving average is $108.01.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the previous year, the firm earned $1.65 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.